<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="by antibiotic-resistant strains, on disease outcomes. We describe possible non-antibiotic" exact="treatment" post="options, when small molecule drugs have no effect on"/>
 <result pre="including their application in combination with chemical antibiotics. secondary bacterial" exact="infection" post="pulmonary viruses SARS-CoV-2 COVID-19 phage therapy phage endolysins fig-count:"/>
 <result pre="was found to be additionally infected with a secondary bacterial" exact="infection" post="with 50% of the fatalities during the SARS-CoV-2 epidemic"/>
 <result pre="Secondary bacterial infections develop in patients during or after initial" exact="infection" post="with an infective pathogen, often a virus (Morris et"/>
 <result pre="Flu pandemic; although clinical records often do now record such" exact="infection" post="complications (Kash and Taubenberger, 2015; MacIntyre et al., 2018)."/>
 <result pre="to support their immune system and prevent progression of the" exact="infection" post="that could lead to the death of the patient"/>
 <result pre="1 Possible clinical progression of patients with a pulmonary virus" exact="infection" post="and prophylaxis or treatment options for bacterial secondary infections."/>
 <result pre="of patients with a pulmonary virus infection and prophylaxis or" exact="treatment" post="options for bacterial secondary infections. Molecular Basis of Manifestation"/>
 <result pre="the defense against a prokaryotic pathogen, is poorly understood. The" exact="prevalence" post="of secondary bacterial infections during a primary virus disease"/>
 <result pre="of the host innate immune response initiated by the viral" exact="infection" post="which facilitates opportunistic bacteria, like Streptococcus to infect the"/>
 <result pre="al., 2011). Cells of a host suffering from a viral" exact="infection" post="are more susceptible to bacterial attachment and colonization (Pittet"/>
 <result pre="infections caused by influenza virus or CoV species; for which" exact="treatment" post="is compromised by secondary bacterial infections (Yang et al.,"/>
 <result pre="et al., 2020; Zhou et al., 2020). While a viral" exact="infection" post="alone can be detrimental to a patient, the pathogen"/>
 <result pre="pneumonia. Half of COVID-19 fatalities experienced some form of secondary" exact="infection" post="(pulmonary or other) that may have contributed to their"/>
 <result pre="SARS-CoV-2 itself or as a result of a secondary bacterial" exact="infection" post="(Tetro, 2020). Patients suffering of a pulmonary virus infection,"/>
 <result pre="in addition to another antibiotic that is deployed once the" exact="infection" post="is identified (Holshue et al., 2020; Wang et al.,"/>
 <result pre="have been reported, but mainly these focus on the viral" exact="infection" post="itself. There are few reports detailing secondary bacterial infections"/>
 <result pre="microbial viruses to kill their host, ideally clearing the bacterial" exact="infection" post="(Altamirano and Barr, 2019). Bacteriophages are naturally occurring viruses"/>
 <result pre="pharmaceutical characteristics of chemical antibiotics, endolysins, and bacteriophages in the" exact="treatment" post="of bacterial infections. A major advantage of phages is"/>
 <result pre="bacterial genus, species or strain, phage therapy offers a promising" exact="treatment" post="option. Clinical studies using phages have demonstrated success at"/>
 <result pre="with a sequential approach of administering the antibiotic after phage" exact="treatment" post="of the biofilm has shown success; initial treatment of"/>
 <result pre="after phage treatment of the biofilm has shown success; initial" exact="treatment" post="of the biofilm with phages caused biofilm disintegration, while"/>
 <result pre="the biofilm (Å�usiak-Szelachowska et al., 2020). Antibiotics administered following biofilm" exact="treatment" post="by phages enhance bacterial reduction Akturk et al., 2019."/>
 <result pre="impact on patient survival, phage libraries, and rapid on-site (hospital)" exact="screening" post="platforms should be made available for use. While phage"/>
 <result pre="patient acceptance, and possibly, adverse immune responses leading to primary" exact="treatment" post="failure. Conclusion Secondary bacterial infections play a critical role"/>
 <result pre="treating secondary bacterial infections. Phage therapy either as a stand-alone" exact="treatment" post="or in combination with antibiotics may offer a valuable"/>
 <result pre="Gram-negative bacteria.Future Microbiol.10377â€&quot;390. 10.2217/fmb.15.825812461 BrookI. (1995). Microbiology of secondary bacterial" exact="infection" post="in scabies lesions.J. Clin. Microbiol.332139â€&quot;2140. 10.1128/jcm.33.8.2139-2140.19957559963 BrookI. (2002). Secondary"/>
 <result pre="E.van MierloM. M.van VeldhuizenJ.van DoornM. B.SchurenF. H.et al. (2019). Endolysin" exact="treatment" post="against Staphylococcus aureus in adults with atopic dermatitis: a"/>
 <result pre="DedrickR. M.Guerrero-BustamanteC. A.GarlenaR. A.RussellD. A.FordK.HarrisK.et al. (2019). Engineered bacteriophages for" exact="treatment" post="of a patient with a disseminated drug-resistant Mycobacterium abscessus.Nat."/>
 <result pre="Sci Biotechnol.251211â€&quot;1215. 10.1007/s10068-016-0192-630263396 KakasisA.PanitsaG. (2019). Bacteriophage therapy as an alternative" exact="treatment" post="for human infections. A comprehensive review.Int. J. Antimicrob. Agents5316â€&quot;21."/>
 <result pre="of print]. 32006750 KimY. G.ParkJ. H.ReimerT.BakerD. P.KawaiT.KumarH.et al. (2011). Viral" exact="infection" post="augments Nod1/2 signaling to potentiate lethality associated with secondary"/>
 <result pre="10.1038/8083311062499 KutterE.De VosD.GvasaliaG.AlavidzeZ.GogokhiaL.KuhlS.et al. (2010). Phage therapy in clinical practice:" exact="treatment" post="of human infections.Curr. Pharm. Biotechnol.1169â€&quot;86. 10.2174/13892011079072540120214609 LiX.GengM.PengY.MengL.LuS. (2020). Molecular"/>
 <result pre="infections.Curr. Pharm. Biotechnol.1169â€&quot;86. 10.2174/13892011079072540120214609 LiX.GengM.PengY.MengL.LuS. (2020). Molecular immune pathogenesis and" exact="diagnosis" post="of COVID-19.J. Pharm. Anal.10102â€&quot;108. 10.1016/j.jpha.2020.03.00132282863 LinD. M.KoskellaB.LinH. C. (2017)."/>
 <result pre="A.BarnesM.RiddaI.SealeH.TomsR.et al. (2018). The role of pneumonia and secondary bacterial" exact="infection" post="in fatal and serious outcomes of pandemic influenza a"/>
 <result pre="Infect. Dis.18:637. 10.1186/s12879-018-3548-030526505 MaharP. D.WasiakJ.ClelandH.PaulE.GinD.WattersD. A.et al. (2014). Secondary bacterial" exact="infection" post="and empirical antibiotic use in toxic epidermal necrolysis patients.J."/>
 <result pre="patients.J. Burn Care Res.35518â€&quot;524. 10.1097/bcr.000000000000006224988228 MalliaP.FootittJ.SoteroR.JepsonA.ContoliM.Trujillo-TorralboM. B.et al. (2012). Rhinovirus" exact="infection" post="induces degradation of antimicrobial peptides and secondary bacterial infection"/>
 <result pre="Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial" exact="infection" post="in chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care"/>
 <result pre="tract infections.Curr. Infect. Dis. Rep.9186â€&quot;192. 10.1007/s11908-007-0030-317430699 NansenA.ThomsenA. R. (2001). Viral" exact="infection" post="causes rapid sensitization to lipopolysaccharide: central role of IFN-Î±Î².J."/>
 <result pre="therapy-advantages over antibiotics?Lancet356:141810.1016/s0140-6736(05)74059-9 PittetL. A.Hall-StoodleyL.RutkowskiM. R.HarmsenA. G. (2010). Influenza virus" exact="infection" post="decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae.Am."/>
 <result pre="pneumonia in Wuhan, China.JAMA3231061â€&quot;1069. WangH.AnthonyD.SelemidisS.VlahosR.BozinovskiS. (2018). Resolving viral-induced secondary bacterial" exact="infection" post="in COPD: A concise review.Front. Immunol.9:2345. 10.3389/fimmu.2018.0234530459754 Weber-DabrowskaB.MulczykM.GÃ³rskiA. (2001)."/>
</results>
